{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:23:12Z","timestamp":1778084592761,"version":"3.51.4"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s10557-022-07336-w","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T07:06:53Z","timestamp":1650870413000},"page":"1225-1237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: a Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Kandavadivu","family":"Umashankar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Mammi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebtissam","family":"Badawoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge C.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Migliore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania A.","family":"Mekary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"7336_CR1","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45:2160\u2013236.","journal-title":"Stroke"},{"key":"7336_CR2","doi-asserted-by":"publisher","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505. https:\/\/doi.org\/10.1136\/bmj.k2505.","DOI":"10.1136\/bmj.k2505"},{"key":"7336_CR3","doi-asserted-by":"publisher","first-page":"e0197583","DOI":"10.1371\/journal.pone.0197583","volume":"13","author":"RCP Makam","year":"2018","unstructured":"Makam RCP, Hoaglin DC, McManus DD, Wang V, Gore JM, Spencer FA, et al. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis. Pizzi C, editor. PLoS ONE. 2018;13:e0197583.","journal-title":"PLoS ONE"},{"key":"7336_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1161\/01.STR.0000198887.81948.74","volume":"37","author":"MJ O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell MJ, Berge E, Sandset PM. Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin? Stroke. 2006;37:452\u20135.","journal-title":"Stroke"},{"key":"7336_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11883-015-0528-3","volume":"17","author":"IM Ruff","year":"2015","unstructured":"Ruff IM, Jindal JA. Use of heparin in acute ischemic stroke: is there still a role? Curr Atheroscler Rep. 2015;17:51.","journal-title":"Curr Atheroscler Rep"},{"key":"7336_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12872-019-1116-1","volume":"19","author":"K Gupta","year":"2019","unstructured":"Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, et al. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment na\u00efve non-valvular atrial fibrillation patients in the US Department of defense population. BMC Cardiovasc Disord. 2019;19:142.","journal-title":"BMC Cardiovasc Disord"},{"key":"7336_CR7","doi-asserted-by":"publisher","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the early management of patients with acute ischemic stroke. Update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the american heart association\/american stroke association. Stroke. 2019;50(12):e344-e418. https:\/\/doi.org\/10.1161\/STR.0000000000000211","DOI":"10.1161\/STR.0000000000000211"},{"key":"7336_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21090","volume":"21","author":"JA Sterne","year":"2017","unstructured":"Sterne JA, Bodalia PN, Bryden PA, Davies PA, L\u00f3pez-L\u00f3pez JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21:1\u2013386.","journal-title":"Health Technol Assess"},{"key":"7336_CR9","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.clinthera.2017.05.358","volume":"39","author":"AR Almutairi","year":"2017","unstructured":"Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, et al. Effectiveness and safety of non\u2013vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther. 2017;39:1456-1478.e36.","journal-title":"Clin Ther"},{"key":"7336_CR10","doi-asserted-by":"publisher","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142.","DOI":"10.1002\/14651858.ED000142"},{"key":"7336_CR11","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med."},{"key":"7336_CR12","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/0140-6736(91)93206-O","volume":"337","author":"J Bamford","year":"1991","unstructured":"Bamford J, Sandercock P, Dennis M, Warlow C, Burn J. Classification and natural history of clinically identifiable subtypes of cerebral infarction. The Lancet. 1991;337:1521\u20136.","journal-title":"The Lancet"},{"key":"7336_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3238165","volume":"2018","author":"ES Donkor","year":"2018","unstructured":"Donkor ES. Stroke in the 2 1 s t century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. 2018;2018:1\u201310.","journal-title":"Stroke Res Treat"},{"key":"7336_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-9-10","volume":"9","author":"SJ Senn","year":"2009","unstructured":"Senn SJ. Overstating the evidence \u2013 double counting in meta-analysis and related problems. BMC Med Res Methodol. 2009;9:10.","journal-title":"BMC Med Res Methodol"},{"key":"7336_CR15","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1016\/j.wneu.2020.06.081","volume":"141","author":"YT Lo","year":"2020","unstructured":"Lo YT, Lim-Watson M, Seo Y, Fluetsch N, Alasmari MM, Alsheikh MY, et al. Long-term opioid prescriptions after spine surgery: a meta-analysis of prevalence and risk factors. World Neurosurg. 2020;141:e894-920.","journal-title":"World Neurosurg"},{"key":"7336_CR16","doi-asserted-by":"publisher","first-page":"g7513","DOI":"10.1136\/bmj.g7513","volume":"349","author":"P Sedgwick","year":"2014","unstructured":"Sedgwick P. Randomised controlled trials: subgroup analyses. BMJ. 2014;349:g7513\u2013g7513.","journal-title":"BMJ"},{"key":"7336_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139\u201345.","journal-title":"Contemp Clin Trials"},{"key":"7336_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"7336_CR19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928\u2013d5928.","journal-title":"BMJ"},{"key":"7336_CR20","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Cerny V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.\u00a0Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 14 Dec 2019."},{"key":"7336_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"7336_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u2013101.","journal-title":"Biometrics"},{"key":"7336_CR23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2017.2161","volume":"74","author":"K-S Hong","year":"2017","unstructured":"Hong K-S, Kwon SU, Lee SH, Lee JS, Kim Y-J, Song T-J, et al. Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation\u2013related mild ischemic stroke: a randomized clinical trial. JAMA Neurol. 2017;74:1206.","journal-title":"JAMA Neurol"},{"key":"7336_CR24","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","volume":"47","author":"NS Rost","year":"2016","unstructured":"Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 2016;47:2075\u201382.","journal-title":"Stroke"},{"key":"7336_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/1708538113490423","volume":"22","author":"L Mao","year":"2014","unstructured":"Mao L, Li C, Li T, Yuan K. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular. 2014;22:252\u20138.","journal-title":"Vascular"},{"key":"7336_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.010","volume":"22","author":"N Tanahashi","year":"2013","unstructured":"Tanahashi N, Hori M, Matsumoto M, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2013;22:1317\u201325.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"7336_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","volume":"11","author":"GJ Hankey","year":"2012","unstructured":"Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315\u201322.","journal-title":"Lancet Neurol"},{"key":"7336_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","volume":"11","author":"JD Easton","year":"2012","unstructured":"Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11:503\u201311.","journal-title":"Lancet Neurol"},{"key":"7336_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","volume":"9","author":"H-C Diener","year":"2010","unstructured":"Diener H-C, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9:1157\u201363.","journal-title":"Lancet Neurol"},{"key":"7336_CR30","doi-asserted-by":"publisher","first-page":"204062232097485","DOI":"10.1177\/2040622320974853","volume":"11","author":"S-F Lin","year":"2020","unstructured":"Lin S-F, Lu Y-H, Bai C-H. Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin. Ther Adv Chronic Dis. 2020;11:204062232097485.","journal-title":"Ther Adv Chronic Dis"},{"key":"7336_CR31","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1161\/STROKEAHA.118.023797","volume":"50","author":"PB Nielsen","year":"2019","unstructured":"Nielsen PB, Skj\u00f8th F, S\u00f8gaard M, Kj\u00e6ldgaard JN, Lip GYH, Larsen TB. Non\u2013vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage. Stroke. 2019;50:939\u201346.","journal-title":"Stroke"},{"key":"7336_CR32","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamaneurol.2019.2099","volume":"76","author":"Y Xian","year":"2019","unstructured":"Xian Y, Xu H, O\u2019Brien EC, Shah S, Thomas L, Pencina MJ, et al. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA Neurol. 2019;76:1192.","journal-title":"JAMA Neurol"},{"key":"7336_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.chest.2018.11.009","volume":"155","author":"H Jung","year":"2019","unstructured":"Jung H, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy. Chest. 2019;155:354\u201363.","journal-title":"Chest"},{"key":"7336_CR34","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1253\/circj.CJ-18-0067","volume":"82","author":"S Yoshimura","year":"2018","unstructured":"Yoshimura S, Koga M, Sato S, Todo K, Yamagami H, Kumamoto M, et al. Two-year outcomes of anticoagulation for acute ischemic stroke with nonvalvular atrial fibrillation - SAMURAI-NVAF study. Circ J. 2018;82:1935\u201342.","journal-title":"Circ J"},{"key":"7336_CR35","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","volume":"49","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke. 2018;49:2933\u201344.","journal-title":"Stroke"},{"key":"7336_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","volume":"50","author":"MS Cho","year":"2019","unstructured":"Cho MS, Yun JE, Park JJ, Kim YJ, Lee J, Kim H, et al. Outcomes after use of standard- and low-dose non\u2013vitamin K oral anticoagulants in Asian patients with atrial fibrillation. Stroke. 2019;50:110\u20138.","journal-title":"Stroke"},{"key":"7336_CR37","doi-asserted-by":"publisher","unstructured":"Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4(4):e001798. https:\/\/doi.org\/10.1161\/JAHA.115.001798.","DOI":"10.1161\/JAHA.115.001798"},{"key":"7336_CR38","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.amjmed.2014.07.023","volume":"127","author":"TB Larsen","year":"2014","unstructured":"Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skj\u00f8th F, Lane DA, Lip GYH. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med. 2014;127:1172-1178.e5.","journal-title":"Am J Med"},{"key":"7336_CR39","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.03.050","volume":"28","author":"M Yokoyama","year":"2019","unstructured":"Yokoyama M, Mizuma A, Terao T, Tanaka F, Nishiyama K, Hasegawa Y, et al. Effectiveness of nonvitamin K antagonist oral anticoagulants and warfarin for preventing further cerebral microbleeds in acute ischemic stroke patients with nonvalvular atrial fibrillation and at least one microbleed: CMB-NOW Multisite Pilot Trial. J Stroke Cerebrovasc Dis. 2019;28:1918\u201325.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"7336_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1474-4422(18)30145-5","volume":"17","author":"D Wilson","year":"2018","unstructured":"Wilson D, Ambler G, Shakeshaft C, Brown MM, Charidimou A, Al-Shahi Salman R, et al. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol. 2018;17:539\u201347.","journal-title":"Lancet Neurol"},{"key":"7336_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.11.032","volume":"27","author":"T Nakase","year":"2018","unstructured":"Nakase T, Moroi J, Ishikawa T. Outcome of secondary stroke prevention in patients taking non\u2013vitamin K antagonist oral anticoagulants. J Stroke Cerebrovasc Dis. 2018;27:1174\u20137.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"7336_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejim.2020.05.020","volume":"80","author":"D Poli","year":"2020","unstructured":"Poli D, Antonucci E, Vignini E, Martinese L, Testa S, Simioni P, et al. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. Eur J Intern Med. 2020;80:73\u20137.","journal-title":"Eur J Intern Med"},{"key":"7336_CR43","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1161\/STROKEAHA.117.017474","volume":"48","author":"CI Coleman","year":"2017","unstructured":"Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48:2142\u20139.","journal-title":"Stroke"},{"key":"7336_CR44","doi-asserted-by":"publisher","first-page":"e206424","DOI":"10.1001\/jamanetworkopen.2020.6424","volume":"3","author":"C-T Tsai","year":"2020","unstructured":"Tsai C-T, Liao J-N, Chiang C-E, Lin Y-J, Chang S-L, Lo L-W, et al. Association of ischemic stroke, major bleeding, and other adverse events with warfarin use vs non\u2013vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation with a history of intracranial hemorrhage. JAMA Netw Open. 2020;3:e206424.","journal-title":"JAMA Netw Open"},{"key":"7336_CR45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/STROKEAHA.119.028030","volume":"51","author":"S-R Lee","year":"2020","unstructured":"Lee S-R, Choi E-K, Kwon S, Jung J-H, Han K-D, Cha M-J, et al. Oral anticoagulation in Asian patients with atrial fibrillation and a history of intracranial hemorrhage. Stroke. 2020;51:416\u201323.","journal-title":"Stroke"},{"key":"7336_CR46","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/ijcp.12863","volume":"70","author":"GYH Lip","year":"2016","unstructured":"Lip GYH, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a \u201creal-world\u201d observational study in the United States. Int J Clin Pract. 2016;70:752\u201363.","journal-title":"Int J Clin Pract"},{"key":"7336_CR47","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. Warfarin in Japanese patients with atrial fibrillation. Circ J. 2012;76:2104\u201311.","journal-title":"Circ J"},{"key":"7336_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"7336_CR49","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"7336_CR50","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"7336_CR51","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"7336_CR52","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","volume":"157","author":"SS Adam","year":"2012","unstructured":"Adam SS, McDuffie JR, Ortel TL, Williams JW. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157:796\u2013807.","journal-title":"Ann Intern Med"},{"key":"7336_CR53","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.thromres.2014.10.002","volume":"134","author":"R Provid\u00eancia","year":"2014","unstructured":"Provid\u00eancia R, Grove EL, Husted S, Barra S, Boveda S, Morais J. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res. 2014;134:1253\u201364.","journal-title":"Thromb Res"},{"key":"7336_CR54","doi-asserted-by":"publisher","unstructured":"Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol. 2013;167(4):1237\u201341. https:\/\/doi.org\/10.1016\/j.ijcard.2012.03.148.","DOI":"10.1016\/j.ijcard.2012.03.148"},{"key":"7336_CR55","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/FJC.0000000000000129","volume":"64","author":"B Jia","year":"2014","unstructured":"Jia B, Lynn HS, Rong F, Zhang W. Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation. J Cardiovasc Pharmacol. 2014;64:368\u201374.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7336_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/clc.22081","volume":"36","author":"A Dogliotti","year":"2013","unstructured":"Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol. 2013;36:61\u20137.","journal-title":"Clin Cardiol"},{"key":"7336_CR57","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1161\/CIRCOUTCOMES.112.966572","volume":"5","author":"WL Baker","year":"2012","unstructured":"Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:711\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"7336_CR58","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","volume":"126","author":"F Dentali","year":"2012","unstructured":"Dentali F, Riva N, Crowther M, Turpie AGG, Lip GYH, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381\u201391.","journal-title":"Circulation"},{"key":"7336_CR59","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","volume":"60","author":"GYH Lip","year":"2012","unstructured":"Lip GYH, Larsen TB, Skj\u00f8th F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60:738\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"7336_CR60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","volume":"110","author":"CS Miller","year":"2012","unstructured":"Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453\u201360.","journal-title":"Am J Cardiol"},{"key":"7336_CR61","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1161\/CIRCOUTCOMES.112.965988","volume":"5","author":"S Schneeweiss","year":"2012","unstructured":"Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:480\u20136.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"7336_CR62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10557-012-6426-9","volume":"27","author":"JSW Kwong","year":"2013","unstructured":"Kwong JSW, Lam Y-Y, Yan BP, Yu C-M. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther. 2013;27:23\u201335.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7336_CR63","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","volume":"123","author":"AH Malik","year":"2019","unstructured":"Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. Am J Cardiol. 2019;123:2051\u20137.","journal-title":"Am J Cardiol"},{"key":"7336_CR64","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.","journal-title":"BMJ."},{"key":"7336_CR65","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/CIRCULATIONAHA.114.013267","volume":"132","author":"M Sharma","year":"2015","unstructured":"Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015;132:194\u2013204.","journal-title":"Circulation"},{"key":"7336_CR66","first-page":"860","volume":"38","author":"H-C Diener","year":"2017","unstructured":"Diener H-C, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017;38:860\u20138.","journal-title":"Eur Heart J"},{"key":"7336_CR67","doi-asserted-by":"publisher","first-page":"e7097","DOI":"10.1136\/bmj.e7097","volume":"345","author":"LH Rasmussen","year":"2012","unstructured":"Rasmussen LH, Larsen TB, Graungaard T, Skjoth F, Lip GYH. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012;345:e7097\u2013e7097.","journal-title":"BMJ"},{"key":"7336_CR68","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1161\/STROKEAHA.112.673558","volume":"43","author":"G Ntaios","year":"2012","unstructured":"Ntaios G, Papavasileiou V, Diener H-C, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43:3298\u2013304.","journal-title":"Stroke"},{"key":"7336_CR69","doi-asserted-by":"publisher","first-page":"e77694","DOI":"10.1371\/journal.pone.0077694","volume":"8","author":"P Sardar","year":"2013","unstructured":"Sardar P, Chatterjee S, Wu W-C, Lichstein E, Ghosh J, Aikat S, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. Meisel A, editor. PLoS ONE. 2013;8:e77694.","journal-title":"PLoS ONE."},{"key":"7336_CR70","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"key":"7336_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1753944718787384","volume":"12","author":"ZA Stacy","year":"2018","unstructured":"Stacy ZA, Richter SK. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations. Ther Adv Cardiovasc Dis. 2018;12:247\u201362.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"7336_CR72","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40261-020-00967-7","volume":"40","author":"S Frol","year":"2020","unstructured":"Frol S, Sernec LP, Hudnik LK, \u0160abovi\u010d M, Oblak JP. Effectiveness and safety of direct oral anticoagulants in the secondary stroke prevention of elderly patients: Ljubljana Registry of Secondary Stroke Prevention. Clin Drug Investig. 2020;40:1053\u201361.","journal-title":"Clin Drug Investig"},{"key":"7336_CR73","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10557-020-06961-7","volume":"34","author":"X Liu","year":"2020","unstructured":"Liu X, Xu Z-X, Yu P, Yuan P, Zhu W-G. Non-vitamin K antagonist oral anticoagulants in secondary stroke prevention in atrial fibrillation patients: an updated analysis by adding observational studies. Cardiovasc Drugs Ther. 2020;34:569\u201378.","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07336-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T09:14:58Z","timestamp":1702545298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07336-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["7336"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07336-w","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"14 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was not required for this study, as it is solely based on previously published data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}